Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat.com A Fresh IPO That Long-Term Investors Shouldn't IgnoreAuthored by Jordan Chussler. Published: 1/14/2026. 
At a Glance - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful often offer considerable short-term upside potential. Of course, they also carry substantial downside risk. Even so, some recent IPOs may justify a place in buy-and-hold portfolios, including a biotechnology company in the healthcare sector that just went public. Last Year's IPO Success Stories Last year illustrates why IPOs shouldn't be dismissed by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since its debut. Short-term speculators may have capitalized on a peak gain of nearly 359% within 30 days of listing, but longer-term holders are still enjoying strong returns. Others, such as Medline (NASDAQ: MDLN), refute the misconception that IPOs are limited to nascent startups. The medical products and services provider, which publicly debuted in December 2025, was founded in 1966 and already boasts a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its ubiquitous packages of bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44%, or $1 per share annually, making it an immediate consideration for income investors. After its IPO, with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out particular cells (for example, cancer cells) to deliver localized doses of radiation, thereby minimizing harm to healthy tissue that could be affected by conventional radiation treatments. According to industry consultancy Grand View Research, the global nuclear medicine market was estimated at nearly $18 billion in 2024 and is forecast to reach nearly $35 billion by 2030, representing a compound annual growth rate of about 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States as the predominant player. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPO activity to rebound in 2026 after funding reductions in 2025 notably slowed healthcare listings. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised $318 million—one of the largest biotech IPO raises in recent memory. The firm now has a market cap of about $3.34 billion. According to the company's prospectus, its executive team includes drug development, approval and commercialization experts, and management has participated in bringing 14 currently FDA-approved products to market. At a technical level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer drugs that use proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Notably, Aktis is a clinical-stage, pre-revenue company. That did not deter Eli Lilly (NYSE: LLY) from anchoring its IPO and making a significant investment. According to Reuters, Eli Lilly purchased $100 million worth of AKTS shares. That purchase builds on a 2024 partnership between the two companies to develop tumor-targeting radiopharmaceuticals. As part of that agreement, Eli Lilly committed $60 million in cash alongside an equity investment in Aktis, with potential milestone payments exceeding $1 billion. The significance of Eli Lilly's backing cannot be overstated. At roughly $1.01 trillion, Lilly is among the largest pharmaceutical companies by market cap after net income jumped nearly 109% year-over-year from 2023 to 2024. That trend is likely to continue when Eli Lilly reports Q4 and full-year 2025 financials on Feb. 5. Between its equity stake and the recent $100 million purchase of AKTS shares, the maker of Zepbound now has a sizable financial interest in the biotech startup's success.
| 
